Presented By: Kristina Kudelko, MD, Clinical Associate Professor, Adult Pulmonary, Hypertension Program, Division of Pulmonary and Critical Care Medicine, Stanford University
Lunch is provided

Pulmonary hypertension still has a horrible prognosis. It’s a progressive disease with no cure. We are much better at identifying and treating it these days, but with the best of therapies, there is at best a 70 percent survival rate at five years. That’s hard. And it affects a lot of young women.

Desired Outcomes:

• describe front-line pulmonary hypertension (PH) diagnostic testing
• interpret the importance of accurate phenotyping of the PH patient
• describe the three main class of PH therapy
• recognize the need for prompt referral to PH centers in specific cases

Learn more at NMCCME.com